SG&A Efficiency Analysis: Comparing Biogen Inc. and Bio-Techne Corporation

SG&A Efficiency: A Tale of Two Biotech Giants

In the competitive world of biotechnology, managing operational costs is crucial. Over the past decade, Biogen Inc. and Bio-Techne Corporation have showcased contrasting strategies in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Biogen's SG&A expenses fluctuated, peaking in 2021 with a 20% increase from 2014. Meanwhile, Bio-Techne's expenses surged by over 500% during the same period, reflecting its aggressive expansion strategy. Notably, Biogen's expenses remained consistently higher, averaging around 10 times those of Bio-Techne. However, the data for 2024 is incomplete, leaving room for speculation on future trends. This analysis highlights the diverse approaches these companies take in managing their operational costs, offering insights into their strategic priorities and market positioning. As the biotech industry evolves, understanding these financial dynamics becomes essential for investors and stakeholders alike.

Key Insight: Biogen vs. Bio-Techne - A Decade of SG&A Strategies